Business websites
Business websites
J&J Innovative Medicine
J&J MedTech
J&J Innovative Medicine
J&J MedTech
Location
Language
English
Choose your country or region
China
中国人
France
Français
India
English
Japan
日本
Switzerland
Deutsch
English
Français
US
English
UK
English
Latest news
Innovation
Caring & giving
Personal stories
Health & wellness
Our Company
Discover J&J
Our Credo
Our Leadership
Code of Business Conduct
Corporate reports
Our culture of inclusion
ESG Policies & Positions
Innovation at J&J
Uniting science and technology
Office of the Chief Medical Officer
Veterans, military & military families
Innovative Medicine
MedTech
Our societal impact
Global Health Equity
Global environmental sustainability
Suppliers
Responsible supply base
Supplier-enabled innovation
Supplier resources
Our history
Careers
Search jobs
Life at J&J
Employee benefits
Professional development
Employee stories
Inclusion
Our teams
Oncology
Immunology
Data science
Market access
Medical affairs
Innovation, development and partnerships
MedTech and surgical robotics
Locations
North America
EMEA
Asia Pacific
Latin America
Student opportunities
Internships
Co-ops
Full-time student jobs
Leadership and development opportunities
How we hire
Application tips
Hiring programs
Hiring FAQs
Join our Global Talent Hub
Investors
Pharmaceutical pipeline
ESG resources
Investor fact sheet
Media Center
Press releases
Menu
Latest news
Innovation
Caring & giving
Personal stories
Health & wellness
Our Company
Discover J&J
Our Credo
Our Leadership
Code of Business Conduct
Corporate reports
Our culture of inclusion
ESG Policies & Positions
Innovation at J&J
Uniting science and technology
Office of the Chief Medical Officer
Veterans, military & military families
Innovative Medicine
MedTech
Our societal impact
Global Health Equity
Global environmental sustainability
Suppliers
Responsible supply base
Supplier-enabled innovation
Supplier resources
Our history
Careers
Search jobs
Life at J&J
Employee benefits
Professional development
Employee stories
Inclusion
Our teams
Oncology
Immunology
Data science
Market access
Medical affairs
Innovation, development and partnerships
MedTech and surgical robotics
Locations
North America
EMEA
Asia Pacific
Latin America
Student opportunities
Internships
Co-ops
Full-time student jobs
Leadership and development opportunities
How we hire
Application tips
Hiring programs
Hiring FAQs
Join our Global Talent Hub
Investors
Pharmaceutical pipeline
ESG resources
Investor fact sheet
Media Center
Press releases
Search Query
Submit Search
Clear
Dictate search request
Search Results
No Results
Recently Viewed
Listening...
Sorry, I don't understand. Please try again
Show Search
Search Results
Search Query
Submit Search
Clear
Dictate search request
Listening...
Sorry, I don't understand. Please try again
126 Results
Categories
All (126)
Caring & giving (1)
Health & wellness (10)
Innovation (13)
Latest news (23)
Our history (9)
Personal stories (8)
Dates
All (126)
Last 7 days (1)
2024 (5)
2023 (6)
2022 (4)
2021 (4)
2020 (3)
2019 (10)
2018 (17)
2017 (11)
2016 (18)
Types
All (126)
Article (31)
Page (1)
Press Release (94)
126 results
for transdermal patches
Filters
Categories
All (126)
Caring & giving (1)
Health & wellness (10)
Innovation (13)
Latest news (23)
Our history (9)
Personal stories (8)
Dates
All (126)
Last 7 days (1)
2024 (5)
2023 (6)
2022 (4)
2021 (4)
2020 (3)
2019 (10)
2018 (17)
2017 (11)
2016 (18)
Types
All (126)
Article (31)
Page (1)
Press Release (94)
Sort By:
Relevance
Relevance
Newest
Oldest
Innovative Medicine
July 16, 2018
Phase 3 CREDENCE Renal Outcomes Trial of INVOKANA® (canagliflozin) is Being Stopped Early for Positive Efficacy Findings
Read more
Innovative Medicine
October 30, 2018
U.S. FDA Approves INVOKANA® (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease
Read more
Innovative Medicine
April 12, 2018
INVOKANA® (canagliflozin) Demonstrated Significant Renal Protective Benefits in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
Read more
Innovative Medicine
March 11, 2018
INVOKANA® (canagliflozin) Significantly Reduces the Risk of Heart Failure- Related Outcomes in Type 2 Diabetes Patients at Risk for or With a History of Cardiovascular Disease
Read more
Corporate
June 29, 2015
STELARA® Receives European Commission Approval For Treatment Of Adolescents With Moderate-To-Severe Psoriasis In Europe
Approval provides new therapeutic option for plaque psoriasis patients aged 12 and older for whom limited approved treatment options are available
Read more
November 3, 2014
#WalkWithD Social Media Campaign Drives Donation to IDF’s Life for a Child Program for Every Hashtag Mention in November
Initiatives Aim to Bring Dignity to All Living with Diabetes and Provide Testing Supplies to Children in Developing Countries
Read more
Innovative Medicine
June 23, 2018
Real-World Evidence Shows Oral INVOKANA® (canagliflozin) Results in Greater Weight Loss and Treatment Adherence Than Injectable GLP-1 Receptor Agonists in Type 2 Diabetes Patients
Read more
Innovative Medicine
April 27, 2018
Real-World Study Shows INVOKANA® (canagliflozin) 300mg Demonstrates Better Blood Glucose Control Than Farxiga® (dapagliflozin) 10mg in Patients with Type 2 Diabetes
Read more
Medical technologies
February 24, 2016
New Onetouch Verio Flex™ Blood Glucose Monitoring System with ColorSure™ Technology Takes the Guesswork Out of Blood Sugar Test Results
-- 9 out of 10 People With Diabetes Agree The System’s Simple Color Range Indicator Helps Them Easily Interpret Their Blood Sugar Readings --
Read more
Innovative Medicine
November 17, 2017
New Real-World Analysis Shows INVOKANA® (canagliflozin) and Other SGLT2 Inhibitors Reduced the Risk of Death and Cardiovascular Events Compared to Other Diabetes Medicines
Read more
7 of 13
Previous
Next
